Astragaloside IV Modulates the Immune Response in Rheumatoid Arthritis and is Associated with Inhibition of the NAV2-Wnt/β-Catenin Signaling Cascade

Background

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint destruction and systemic inflammation, with limited long-term efficacy and clinically important adverse effects of current treatments. Astragaloside IV (ASIV), the core active saponin component isolated from Astragalus membranaceus, has shown anti-inflammatory, immunomodulatory, and joint-protective potential in multiple inflammatory disease models, while its underlying mechanism in RA remains to be fully elucidated.